Physician profile
Mona Bhatti
NPI 1295153906
$1,459.26
in general payments reported to CMS, 2019-2025
23 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $395 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439 · Debt Forgiveness: $20.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.93 |
| Debt Forgiveness | $20.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $274.21 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $204.44 | 2024-2025 | |
| Lilly USA, LLC | $146.41 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $119.17 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $96.60 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $75.50 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $73.37 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $65.63 | 2024-2025 | |
| Pfizer INC. | $44.58 | 2025 | |
| Dexcom, INC. | $42.25 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $39.76 | 2024 | Inspire |
| Lundbeck LLC | $37.25 | 2025 | Vyepti |
| Abbott Laboratories | $36.41 | 2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $32.67 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $22.72 | 2024 | Ycanth |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.24 | 2025 | Jardiance |
| Baxter Healthcare | $20.33 | 2024 | |
| Cequr Corporation | $20.14 | 2025 | Cequr Simplicity |
| Dynavax Technologies Corporation | $19.93 | 2025 | Heplisav-B |
| Amgen INC. | $18.07 | 2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $17.78 | 2025 | Symbravo |
| Beta Bionics, INC. | $16.03 | 2024 | Ilet Bionic Pancreas |
| Shield Therapeutics INC | $14.77 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.